NCT02567214 - Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions

COPD

Interventions

DRUG

Ultibro®

The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.

DRUG

Spiriva®

The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.

Trial Locations (3)

K7L 2V6

Queens University, Kingston

H2W 1S4

McGill University, Montreal

G1V 4G5

Laval University - IUCPQ, Québec